Core Viewpoint - The report from Citi indicates that WuXi AppTec is expected to see a 9% revenue growth in Q4 2025 and a 36% increase in adjusted net profit, surpassing market expectations by 2% and 3% respectively, driven by its strong integrated CRDMO model and robust growth in the WuXi TIDES business, along with China's competitive advantage in the global small molecule supply chain [1] Group 1 - The strong performance of WuXi AppTec is attributed to its comprehensive CRDMO model and the significant growth of its WuXi TIDES business [1] - The company is expected to outperform the market, with adjusted net profit growth projected to be in the high double digits (approximately 16% to 19%) for 2026, exceeding the market expectation of 15% [1] - Citi maintains its forecasts for 2025 to 2027 and has set a target price of HKD 143.4 for WuXi AppTec, rating it as "outperform" in the Chinese CRO/CDMO sector [1]
大行评级|里昂:将药明康德列为中国CRO/CDMO领域首选股 目标价143.4港元